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p<0,05). By the use of binary regression analysis with the building of ROC-curves
we established the values of these STE parameters, obtained within the 1st month
after myocarditis onset, that could be considered as predictors of persistent LV
systolic dysfunction after 1 year of follow-up: LGSS <8,6% (sensitivity – 76%,
specificity 72%), LGSSr <0,63 s–1 (sensitivity – 72%, specificity 78%), CGSS
<8,3% (sensitivity – 80%, specificity 66%).
Conclusion: We detected STE parameters that within the 1st month after my-
ocarditis onset could be used for prognostication of LV systolic dysfunction per-
sistence after 1 year of follow-up: values of LGSS, LGSSr and CGSS.
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Disruption of the sarcoglycan-dystrophin complex in patients with
biopsy-proven myocarditis - novel pathophysiological insights based
on comprehensive analyses of endomyocardial biopsies
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K. Klingel2, A. Yilmaz1. 1University Medical Center, Department of Cardiol-
ogy and Angiology, Münster, Germany; 2University of Tuebingen, Tuebingen,
Germany; 3Robert Bosch Hospital, Stuttgart, Germany
Background: A final common pathway leading to myocardial damage in mus-
cular dystrophy and (viral) myocarditis has been suggested previously based on
invasive animal studies as well as non-invasive clinical imaging studies. In both
diseases, progressive left ventricular dysfunction is thought to be associated with
dystrophin protein disruption. However, respective data in patients with myocardi-
tis are scarce and the pathomechanism of different forms of human myocarditis
leading to dilated cardiomyopathy is still unclear. The present study aimed at eval-
uating the potential disruption of the sarcoglycan-dystrophin complex in patients
with biopsy-proven myocarditis.
Methods and results: Twenty-five patients with biopsy-proven myocarditis (me-
dian 46yrs, 64% male) underwent non-invasive CMR studies comprising cine-
and late gadolinium enhancement (LGE)-imaging (on a 1.5-T scanner) in addition
to comprehensive immunohistological analyses of their endomyocardial biopsy
specimens (taken from the left ventricle) regarding the expression pattern of dys-
trophin and dystrophin-associated glycoproteins such as sarcoglycan.
Regarding CMR parameters, median left ventricular (LV) end-diastolic volume
(EDV) index was 144ml/m2 (IQR 112–173ml/m2), median LV ejection fraction (EF)
24% (IQR 18–33%) and median RV-EF 39% (27–51%). LGE was present in 22/25
patients (88%), exclusively non-ischemic (intramural/subepicardial) in pattern and
involving in the median 2 out of 17 segments. Overall, a deficiency in myocardial
dystrophin expression (either rod domain and/or C- or N-terminal domain) was
observed in 7/25 patients (28%) with biopsy-proven myocarditis. Noteworthy, a
“mosaic” pattern of dystrophin deficiency - that is typically observed in female
carriers of muscular dystrophy - was observed in 5 out of those 7 patients with
myocarditis and deficient dystrophin expression (3 of them with male gender, see
attached figure). Moreover, an additional deficiency in myocardial sarcoglycan
expression was detected in 5 out those 7 patients with deficient dystrophin ex-
pression. In contrast, all patients with normal dystrophin expression also showed
intact sarcoglycan expression.
Dystrophin-stainings
Conclusions: Disruption of the myocardial sarcoglycan-dystrophin complex is
a frequent finding in patients with biopsy-proven myocarditis. In particular, the
observation of a “mosaic” pattern of myocardial dystrophin deficiency deserves
further exploration since it suggests a potentially different pathomechanism of
cell damage in neighbouring cardiomyocytes.
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Approximation of true incidence of myocarditis by systematic
screening of patients with cardiac magnetic resonance imaging after
exclusion of significant coronary artery disease
D. Patriki, E.G. Gresser, R.M. Manka, T.L. Luescher, B.H. Heidecker. University
Heart Center, Zurich, Switzerland
Background: Underdiagnosis of myocarditis remains a clinical dilemma and its
incidence remains uncertain. Postmortem data have implicated myocarditis in
sudden cardiac death at a rate up to 12%, suggesting a considerable number
of cases who remain undiagnosed and untreated. We sought to test the hypoth-
esis that systematic screening of patients presenting with angina-like symptoms,
elevated high sensitivity troponin T (TnT-hs, ≥14ng/l) and no significant coronary
artery disease, by using cardiac magnetic resonance imaging (CMR), will provide
an approximation of the true incidence of myocarditis at our hospital.
Methods: We performed a retrospective chart review of all patients, who pre-
sented with angina-like symptoms and elevated TnT-hs in the years 2015 and
2016. During the year 2015, patients with moderate to high clinical suspicion for
myocarditis underwent CMR. Starting 2016, CMR was obtained in all patients
based on criteria above independent of degree of clinical suspicion for myocardi-
tis. To assess the increase in incidence of myocarditis detected through aggres-
sive screening in 2016, we compared it to the incidence in 2015, when the thresh-
old for screening was still higher.
Results: A total of 2889 patients (77% male, 66±15 years) qualified for our chart
review. Among the most common diagnoses on CMR were myocarditis (8%) and
hypertrophic cardiomyopathy (4%), while 35% of CMR studies were unremark-
able. Fourteen patients did not undergo CMR at our hospital due to contraindica-
tions, claustrophobia or hospital transfer. In the first year, 1001 patients presented
to our hospital with angina-like symptoms and TnT-hs elevation, in the year there-
after it were 1888 patients. In the year 2015, the number of CMR studies was 99
with a subsequent increase to 215 in the year 2016. While in the year 2015, only
4 cases were identified with myocarditis, the number increased 6-fold to a total of
24 in the year 2016 (p-value=0.04).
Conclusion: This is the first study to assess the incidence of myocarditis by
systematic screening with CMR in patients with angina-like symptoms, elevated
TnT-hs and negative coronary angiography. Our data support the hypothesis that
myocarditis continues to be an underdiagnosed illness and its incidence is cur-
rently strongly underestimated. Given the potentially severe adverse outcomes
of myocarditis if left untreated, including malignant arrhythmias and heart failure
secondary to chronic inflammation, we recommend a low threshold for the use of
CMR.
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Introduction: The diagnosis of acute myocarditis (aMyo) needs a high level of
suspicion. Cardiac magnetic resonance (CMR) may contribute to the diagnosis;
but endomyocardial biopsy (EMB) is considered the gold standard, although used
infrequently worldwide. Short-term course, albeit unpredictable is usually benign
and treatment is mainly supportive.
Objectives: To assess the usual care attitudes regarding hospitalized patients
(pts) with a diagnosis of aMyo in Portugal, report patient’s clinical profiles and
current therapeutic approaches, and assess the relevance of CMR to eventual
changes in management and/or therapeutic decisions.
Methods: Prospective nationwide survey of admitted aMyo pts during a 2-year
period (25.04.13–15). Electronic CRFs were completed with admission/discharge
data, diagnostic tests, treatments and open-ended questions to evaluate physi-
cian’s opinions and conclusions.
Results: 248 pts from 18 centers were included, 98% caucasian, 35±14 (18–84)
years old, 83% male. A recent infectious disease was detected in 57.5% (up-
per respiratory tract in 71.2%) and 23% had been previously treated with an-
tibiotics. On admission, presentation included angina-like thoracic pain (96%),
non-CV symptoms- 58.4% (fever-71%, respiratory- 52.8%, GI- 28.1%), heart fail-
ure (HF)- 5.4% and cardiogenic shock- 0.8%; abnormal ECG - 82% (mostly ST
elevation-78.5%); increased troponin levels in 95%; echo (in 94%pts) showed left
ventricular dilatation (LVD) - 5.7%, segmental LV wall abnormalities (segmAbn) -
34%, reduced LV ejection fraction (RLVEF) - 21% and pericardial effusion (PE) -
11.7%. CMR (in 57%pts), didn’t change the management in 70% of cases. Coro-
nary angiography (in 40%) revealed significant CAD in 7.4%. EMB was diagnostic
in the 2 pts in which was performed (due to severe progressive HF). Multiple viral
serologies (in 32.4% pts) were conclusive in only 0.5%. Most pts were treated
with NSAIDs, 39% received ACEi or ARB, 36% a beta-blocker (BB) and 8.4%
diuretics; 3.4% needed inotropes. Only 1 death occurred (shock). At discharge,
an abnormal ECG persisted in 64.4% of pts; echo (in 50.4%) showed LVD in 6%,
segmAbn in 24.6%, RLVEF in 14.6% and PE in 10.2%. Most pts (88.2%) were
discharged on NSAIDs, 37.6% on ACEi or ARB, 30.36% on BB, and 6.47% on
diuretics. Final diagnosis was aMyo in 54.4% (probable/possible in 96.9% and
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“clinical” in 96.4%, supported by lab results in 87.7% and ECG in 68.8%. Echo
or CMR contribution in supporting “clinical diagnosis”, was 38.3% and 48.6% re-
spectively. Disease course was in most cases “mild” (87%).
Conclusions: Echo and CMR were performed in most pts with aMyo but diag-
nosis remained mostly “clinical” according to treating physicians. EMB was very
rarely performed. Treatment was largely empirical but an “overuse” of CV drugs
and NSAIDs was observed.
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Identification of serum apurinic/apyrimidinic endonuclease 1/redox
effector factor-1 (APE1/Ref-1) in mouse model of viral myocarditis;
implication of a novel biomarker for myocarditis
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Introduction: Myocarditis is the major cause of sudden death in young adults.
However, the utility of endomyocardial biopsy that is the gold standard for a defi-
nite diagnosis of acute myocarditis is limited because of sampling error and vari-
ability in observer interpretation. Apurinic/apyrimidinic endonuclease 1/redox ef-
fector factor-1 (APE1/Ref-1) is a multifunctional protein which is involved in DNA
base excision repair pathway and in transcriptional regulation of gene expression.
Elevation of serum APE1/Ref-1 is shown in various diseases including hyperten-
sion and ischemic heart disease.
Purpose: We investigated serum APE1/Ref-1 in murine myocarditis models to
verify the potential of it as a biomarker for the definite diagnosis and severity
evaluation of acute viral myocarditis.
Methods: Coxsackievirus was used to induce acute myocarditis in mice. The
serum APE1/Ref-1, NT-proBNP and troponin I was measured with sandwich
enzyme-linked immunosorbent assay from mice model of acute viral myocardi-
tis. The histologic examination and viable virus titers measurements from their
hearts were performed.
Results: The serum troponin I was significantly increased at day 3 (0.89±0.37
ng/mL), peaked to day 7 (1.37±0.43 ng/mL) and normalized at day 10. The serum
NT-proBNP was significantly increased at day 3 (701.71±151.38 ng/mL), per-
sisted to day 7 (341.28±83.68 ng/mL) and decreased at day 10 (170.25±49.73
ng/mL). Serum troponin I levels were correlated with NT-proBNP (R=0.586,
p<0.01). The serum levels of APE1/Ref-1 were gradually increased until 10
days after infection (day 3 vs. day 7 vs. day 10; 7.05±1.25 vs. 8.68±0.75 vs.
10.74±1.64 ng/mL). Myocardial inflammation was mild at day 3, peaked at day
7, and markedly decreased at day 10. Viable virus titers in the hearts peaked at
3 days after infection, decreased at day7 and 10 (day 3 vs. day 7 vs. day 10;
5.52±0.44 vs. 3.52±0.65 vs. 2.05±0.07 log PFU/mg heart). Both serum troponin I
and APE1/Ref-1 were positively correlated with the degrees of myocardial inflam-
mation. Especially, serum APE1/Ref-1 showed a stronger association (R=0.352,
p<0.05 in serum troponin I vs. R=0.750, p<0.01 in serum APE1/Ref-1).
Serum APE1/Ref-1 in myocarditis.
Conclusions: The levels of serum APE1/Ref-1 are elevated till late stage in acute
myocarditis. They are correlated with the degrees of myocarditis, reflecting the
severity of myocardial damage. We suggest that serum APE1/Ref-1 can serve as
a novel biomarker for acute myocarditis.
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Endomyocardial biopsy of the right ventricular septum: a safe and
accurate technique for the diagnosis of clinically suspected
inflammatory cardiomyopathy
G. Peretto1, S. Sala1, S. Rizzo2, C. Basso2, G. Thiene2, P. Della Bella1. 1San
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Background: Endomyocardial biopsy (EMB) represents the gold standard tech-
nique for the diagnosis of inflammatory cardiomyopathy (ICMP). According to
some authors, its sensitivity is significantly improved when EMB is guided by
late gadolinium enhancement (LGE) at cardiac magnetic resonance (CMR) or by
electro-anatomical mapping (EAM). However, these procedures are often com-
plex and time-consuming. Moreover, the risk of complications increases, as far
as EMB is performed away from the right ventricular septum (RVS), which is the
simplest and safest area to sample.
Purpose: We show that, in patients with clinically suspect ICMP, performing an
EMB by sampling the RVS only, is accurate enough to reach a diagnosis, despite
of the presence of locally abnormal signals at CMR or EAM.
Methods: We analysed 87 patients with the clinical suspicion of ICM. All of them
had evidence of normal coronary arteries and underwent both CMR and EMB.
EMB was performed percutaneously via trans-jugular access, guided by fluo-
roscopy and trans-thoracic echocardiogram. Five samples of myocardium were
obtained from RVS in all of the patients, wherever LGE was found at CMR.
Histopathological results were compared with CMR findings. In patients present-
ing with ventricular arrhythmias and indication to substrate ablation, EAM was
also available for comparison.
Results: Overall, 62 patients (71.3%) had a histopathological diagnosis of ICMP,
while 15 (17.2%) had a different but defined diagnosis. Nonspecific EMB was
found in 10 patients only (11.5%), with CMR suggesting a defined diagnosis in
5/10 cases. CMR showed LGE in 75/87 cases (86.2%, 55/62 ICMP vs. 20/25 non-
ICMP, p=n.s.), involving the interventricular septum in 34/87 (39.1%, 25/62 ICMP
vs. 9/25 non-ICMP, p=n.s) and the RVS in 7/87 (8.0%, 5/62 ICMP vs. 2/25 non-
ICMP, p=n.s.) patients only. In patients with arrhythmic presentation undergone
EAM, substrate map showed abnormal potentials involving the RVS in 4/11 ICMP
vs. 1/8 non-ICMP (p=n.s.). Overall, diagnostic sensitivity for RVS sampling was
88.5%: 91.1% vs. 87.8% vs. 83.3% when abnormal CMR/EAM signals were found
within interventricular septum (31/34) vs. were found elsewhere (36/41) vs. were
absent (10/12), respectively (p=n.s.). Of note, a definite histological diagnosis
was obtained in 10/87 patients (11.5%) despite any evidence of LGE or abnormal
EAM. Minor complications occurred, since one patient only (1.1%) underwent
mild self-limited pericardial effusion.
Conclusion: In patients with clinically suspected ICMP, EMB can be performed
by sampling just the RVS, allowing for a definite diagnosis in 88.5% of cases.
This technique is safe, and shows an acceptable sensitivity even when CMR/EAM
shows no local abnormalities or completely normal findings.
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Multi-modality approach in the diagnosis of chronic myocarditis with
preserved left ventricular ejection fraction: the role of 2D
speckle-tracking echocardiography
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Background: Up to one third of the patients with myocarditis (MC) have a pre-
served left ventricular ejection fraction (MCpEF), which remains difficult to diag-
nose, especially when the patients present in the chronic phase of the disease.
Purpose: The purpose of our study was to evaluate the role of adding two-
dimensional (2D) speckle-tracking echocardiography (STE) to cardiac magnetic
resonance imaging (cMRI) in the evaluation of patients with suspected MCpEF
and prolonged duration of clinical presentation.
Methods: We analyzed 67 patients with suspected chronic MCpEF who under-
went endomyocardial biopsies (EMBs). In all patients, 2D STE and cMRI were
performed within 48 hours before EMBs.
Results: Thirty-two patients with confirmed chronic inflammation served as study
group (MCpEF) and the remaining patients (n=35) served as control group. Pa-
tients with MCpEF had significantly lower left ventricular global longitudinal sys-
tolic strain (GLS) than controls (GLS: -17.01±2.42% vs. -19.39±3.81%, p<0.001).
In line, GLS had an adequate diagnostic performance to detect MCpEF (sensi-
tivity, specificity, and accuracy of 82%, 70%, and 76%), which was better than
using the current Lake-Louise criteria with cMRI (sensitivity, specificity, and ac-
curacy 54%, 71%, and 67%; respectively). In addition, adding GLS to the Lake-
Louise criteria improved significantly the diagnostic performance of cMRI to detect
MCpEF (sensitivity, specificity, and accuracy 96%, 55%, and 75%, respectively).
Conclusion: 2D STE play a useful role in the current evaluation of patients with
suspected chronic myocarditis with preserved left ventricular ejection fraction.
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ISG15-dependent susceptibility to troponin I induced autoimmune
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Cardiology, Heidelberg, Germany; 2Charite - Campus Mitte (CCM), Institute for
Biochemistry, Berlin, Germany
Background: One leading cause of heart failure in young adults is the mani-
festation of a myocarditis. The underlying factors for predisposition towards the
development of autoimmune myocarditis are unknown. Mice represent a suitable
model to mimic the divergent disease progression observed in humans. Likewise,
BALB/c mice are susceptible to the induction of an experimental autoimmune my-
ocarditis (EAM), whereas C57BL/6 mice are not. The identification of molecular
targets affecting disease susceptibility is a prerequisite for the identification of
novel therapeutic approaches. One of these molecular targets is the interferon
stimulated gene of 15 kDa (ISG15). The ISG15 system is crucial for determining
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